z-logo
open-access-imgOpen Access
Prevalence of IgA antitissue transglutaminase antibodies in children with type 1 diabetes mellitus
Author(s) -
Gabriel Samaşca,
Mihaela Iancu,
Angela Butnariu,
Mariana Andreica,
Doru Dejica
Publication year - 2011
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.20449
Subject(s) - tissue transglutaminase , medicine , asymptomatic , diabetes mellitus , antibody , type 2 diabetes mellitus , serology , disease , type 1 diabetes , gastroenterology , immunology , endocrinology , biology , enzyme , biochemistry
The association of celiac disease with type 1 diabetes mellitus is known, but the evolution of celiac disease is most frequently asymptomatic, without any clinical signs. Thus, diagnosis is impossible to make in the absence of serological tests. Our study aimed to determine the prevalence and the efficiency of IgA antitissue transglutaminase antibodies in the screening of celiac disease in children with type 1 diabetes mellitus. Method : During the course of 2008–2009, we performed an analytical clinical study that included the determination of IgA antitissue transglutaminase antibodies in a group of 119 children with type 1 diabetesmellitus. Fifty‐seven percent of the subjects were male and 43% were female, with a mean age of 11±4 years. Results : By evaluating IgA antitissue transglutaminase antibodies, we obtained a prevalence of 9.2% in children with type 1 diabetes mellitus, with a sensitivity and specificity of 80 and 82.6%, respectively. Conclusions : There is an increased prevalence of IgA antitissue transglutaminase antibodies, which suggests the need to use this method as an effective first‐line test in the screening of celiac disease in children with type 1 diabetes mellitus. J. Clin. Lab. Anal. 25:156–161, 2011. © 2011 Wiley‐Liss, Inc.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here